TRIUMPH-Outcomes is not required for initial obesity approval but will be critical for long-term payer and labeling decisions
***Based on a 6-month clinical trial (n=180) of individuals who were enrolled between FebruaryApril 2024, with overweight or obesity taking semaglutide or tirzepatide for weight loss and related outcomes through the WW Clinic Program and participating in the GLP-1 companion nutrition program
The aim of our study was to investigate specific types of microbiota-derived metabolites, especially bile acids, short-chain fatty acids, vitamins, amino acids, serotonin and hypoxanthine, which are all implicated in the pathogenesis of IBS
Other Considerations While action of GLP-1 on pancreatic -cells increases insulin release, this hormone and its analogs have key impact on gastric emptying and satiety
While the inherent pharmacokinetic properties of each GLP-1 receptor agonist largely determine elimination time, several patient-specific factors can influence how quickly or slowly these medications clear from the body
In clinical trials, 7%--13% of people taking Wegovy experienced burping
